2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-12294B
    (Rac)-PEAQX 2514919-70-9 98%
    (Rac)-PEAQX is a NMDA receptor agonist. (Rac)-PEAQX can promote the activation of caspase-3 and induce cell apoptosis in cortical striatal slice cultures .
    (Rac)-PEAQX
  • HY-122957
    Huperzine C 163089-71-2 98%
    Huperzine C is an alkaloid isolated from Huperzia serrate. Huperzine C is an acetylcholinesterase (AChE) inhibotor, with an IC50 of 0.6 μM. Huperzine C can be used for the research of Alzheimer’s disease.
    Huperzine C
  • HY-122968
    Brocresine 555-65-7 98%
    Brocresine (NSD-1065) is an orally active histidine decarboxylase inhibitor and inhibits the formation of histamine from histidine. Brocresine is also a L-amino acid decarboxylase inhibitor with both a peripheral and central action. Brocresine inhibits gastric secretory response to administration of exogenous gastrin.
    Brocresine
  • HY-122991
    Prospasmine hydrochloride 132-45-6 98%
    Prospasmine hydrochloride is an anticholinergic drug that has the activity of inhibiting glandular secretions and relaxing smooth muscles. Prospasmine hydrochloride is mainly used to inhibit certain types of gastrointestinal disorders. Prospasmine hydrochloride helps relieve pain caused by smooth muscle spasms. Prospasmine hydrochloride is also used as an anesthetic adjuvant in some cases.
    Prospasmine hydrochloride
  • HY-123006
    Aszonalenin 81797-27-5 98%
    Aszonalenin is a metabolite of Aspergillus zonatus.
    Aszonalenin
  • HY-123015
    Tamolarizine 93035-32-6 98%
    Tamolarizine is a calcium channel blocker. Tamolarizine crosses the blood-brain barrier and antagonizes the effects of calcium on neurons. Tamolarizine can be used in nervous system research.
    Tamolarizine
  • HY-123044
    Tedatioxetine 508233-95-2 98%
    Tedatioxetine (Lu AA24530) acts as a serotonin and norepinephrine (NE)-preferring triple reuptake inhibitor (TRI) and 5-HT2A, 5-HT2C, 5-HT3 and α1A-adrenergic receptor antagonist.
    Tedatioxetine
  • HY-123050
    (Rac)-SAR131675 1092539-44-0 98%
    (Rac)-SAR131675 is the racemate of SAR131675. SAR131675 is a potent and selective VEGFR3 inhibitor with an IC50 of 23 nM.
    (Rac)-SAR131675
  • HY-123138
    LY206130 free base 127414-58-8 98%
    LY206130 free base is a 5-HT1A receptor antagonist with the activity of enhancing exogenous serotonin levels. LY206130 free base, when used concomitantly with fluoxetine, may enhance the appetite-suppressing effects of fluoxetine. LY206130 free base was shown to significantly reduce sweetened milk concentrate consumption in a dietary model. Clinical application of LY206130 free base may be beneficial in curbing eating disorders and obesity.
    LY206130 free base
  • HY-123139
    Flutroline 70801-02-4 98%
    Flutroline (CP-36584), a tetrahydro-7-carboline compound, is an orally active and potent anti-psychotic compound.
    Flutroline
  • HY-123184
    S 1924 111371-30-3 98%
    S 1924 is a potent H+, K+-ATPase inhibitor, with IC50 values of 10.3 and 1.6 μM at pH 7.4 and pH 6.0, respectively.
    S 1924
  • HY-123189
    LY 171859 89139-28-6 98%
    LY 171859 is a D2 receptor agonist with significant reductase activity. LY 171859 exhibits enzymatic activity in the cytoplasm of liver, lung, and kidney, and also contains significant reductase activity in rat and human blood. LY 171859 has higher hepatic reductase activity in guinea pigs, followed by hamsters, rabbits, rats, and mice. The substrate of LY 171859 shows an apparent Km of 5.6 μM. The reduction reaction of LY 171859 is NADPH-dependent with an apparent Km of 14.8 μM. Only the A-side hydrogen of NADPH is incorporated in the reduction product of LY 171859. The reaction of LY 171859 is inhibited by cyanide and thiol reagents, and phenobarbital does not induce its activity in rats.
    LY 171859
  • HY-123199
    Serotonin azidobenzamidine 98409-42-8 98%
    Serotonin azidobenzamidine is an arylazido derivative of 5-hydroxytryptamine (HY-B1473A). Serotonin azidobenzamide competitively inhibits [3H]5-hydroxytryptamine uptake by rat cortical synaptosomes in the dark with a Ki of 130 nM.
    Serotonin azidobenzamidine
  • HY-123222
    CGP 56999 153994-97-9 98%
    CGP 56999 is a potent antagonist GABA(B) receptor, with the IC50 of 0.002 μM. CGP 56999 increased the levels of BDNF mRNA in the brain in vivo and in vitro.
    CGP 56999
  • HY-123229
    Ropizine 3601-19-2 98%
    Ropizine (SC 13504) is a benzhydryl piperazine with anticonvulsant properties.
    Ropizine
  • HY-123239
    KLS-13019 1801243-39-9 98%
    KLS-13019 is an orally active GPR55 receptor antagonist and a structural analogue of cannabidiol (CBD). It can prevent and reverse chemotherapy-induced peripheral neuropathy (CIPN) in a dose-dependent manner in rats.
    KLS-13019
  • HY-123240
    CI-966 110283-79-9 98%
    CI-966 is a potent, selective, orally active and brain-penetrant inhibitor of the GABA transporter GAT-1, with IC50s of 0.26 μM and 1.2 μM for hGAT-1, rGAT-1, respectively. CI-966 shows more than 200-fold selectivity over GAT-2, GAT-3, and BGT-3. CI-966 exhibits anticonvulsant and neuroprotective activities.
    CI-966
  • HY-123249
    HZ166 612527-56-7 98%
    HZ166 is a GABAA receptor subtype-selective benzodiazepine site agonist with preferential activity at α2- and α3-GABAA receptors. HZ166 shows anti-hyperalgesic effects. HZ166 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    HZ166
  • HY-123272
    E6801 528859-04-3 98%
    E6801 is a 5-HT6 receptor agonist that improves recognition memory by jointly modulating cholinergic and glutamatergic neurotransmission. E6801 can be used in studies of dementia, depression, obesity, epilepsy, etc.
    E6801
  • HY-123294
    Fentrazamide 158237-07-1 98%
    Fentrazamide (YRC 2388) is a herbicide. Fentrazamide has specific toxic effects on the nervous system and erythrocytes in rats, affecting the energy supply of cells mainly by interfering with the glycolysis process. Fentrazamide can be used as a useful tool to study the mechanisms of neurodegenerative diseases and erythrocyte dysfunction.
    Fentrazamide
Cat. No. Product Name / Synonyms Application Reactivity